New hope for oral leukoplakia: light therapy vs. cream in Head-to-Head trial
NCT ID NCT07453472
First seen Mar 14, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study tests two non-invasive treatments for oral leukoplakia, a condition that can turn into mouth cancer. About 166 adults with the condition will receive either a light-activated therapy (photodynamic therapy) or a vitamin D-based cream (calcipotriol) for 4 weeks. The goal is to see which treatment better shrinks or removes the abnormal mouth patches and improves quality of life, while tracking side effects and recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LEUKOPLAKIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
All India Institute of Medical Sciences New Delhi
New Delhi, National Capital Territory of Delhi, 110029, India
Conditions
Explore the condition pages connected to this study.